^
    5ms
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    DR30303
    11ms
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Sep 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    DR30303
    2years
    A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd.
    New P1 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    DR30303